Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Venetoclax and Azacitidine and Lintuzumab-Ac225 in Patients With Refractory or Relapsed AML

NCT03932318 is registered in ClinicalTrials.gov with Actinium Pharmaceuticals as lead sponsor.

NCT NCT03932318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03932318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Venetoclax and Azacitidine and Lintuzumab-Ac225 in Patients With Refractory or Relapsed AML
Lead sponsor
Actinium Pharmaceuticals
Phase
Phase 1/2
Overall status
Withdrawn
Start date
March 31, 2023
Completion date
September 30, 2024
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, relapsed adult aml